#PrecisionTreatment Archives

ASCO-GU Interview | Dr. Fufu Zheng Shares Advances in First-Line PARPi Treatment and Genetic Testing for mCRPC

By Mourabit Halima 2024.03.04

Editor's note: At the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2024) held recently, data on patients with homologous recombination repair mutations (HRRm) from the PROpel study…

ASCO-GU Interview | Dr. Shun Zhang: The Value and Development of Genetic Testing in Precision Treatment of Prostate Cancer

By Mourabit Halima 2024.03.04

Editor's note: Precision treatment begins with testing. PARP inhibitors (PARPi) such as olaparib have become a precision treatment option for metastatic castration-resistant prostate cancer (mCRPC), offering therapeutic benefits to patients…

ASCO-GU Interview | Dr. Qiang Wei: Embracing the Era of Precision Treatment, Offering Personalized Treatment Through Multidisciplinary Management

By Mourabit Halima 2024.03.04

Editor's Note: Prostate cancer is the most common "silent killer" threatening men's health worldwide, with traditional treatments primarily involving surgery, radiation therapy, chemotherapy, and hormonal therapy. In recent years, the…